| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Delamination of the metal matrix (MMP) and extracellular matrix (ECM) is strongly inhibited by the tumor cell line IPR-803 MDA-MB-231 [1]. IPR-803 promotes apoptosis at a concentration that is concerning for damage, with an IC50 of roughly 30 μM, and destroys MDA-MB-231 cytochromes [1]. MDA-MB-231 cells are stimulated to grow by IPR-803 at an IC50 of 58 μM[1]. IPR-803 (1-50 μM; 24 hours) (0-200 μM; 3 days) boils MDA-MB-231 cells for the least amount of time, with the compound's cytotoxicity causing the least amount of cell inhibition [1]. It has been demonstrated that IPR-803 (50 μM; 30 minutes) inhibits MAPK phosphorylation [1].
|
|---|---|
| ln Vivo |
For five weeks, IPR-803 (200 mg/kg; ig; three times a week) can increase body weight, however there isn't a statistically significant difference between the treated and untreated groups [1]. With a gradient of 4% and poor sidewall bioavailability, IPR-803 remains highly concentrated in tumor tissue even after 10 hours [1]. The half-life (t1/2) of IPR-803 is 5[1].
|
| Cell Assay |
Cell proliferation experiment[1]
Cell Types: MDA-MB-231 Cell Tested Concentrations: 0 μM, 50 μM, 150 μM, 200 μM Incubation Duration: 3 days Experimental Results: Shows 90% invasion blocking rate observed at 50 μM . |
| Animal Protocol |
Animal/Disease Models: MDA NSG mouse-MB-231 cell xenograft [1]
Doses: 200 mg/kg Route of Administration: po (oral gavage); three times a week; continued for 5 weeks Experimental Results: Impaired lung metastasis. Animal/Disease Models: NOD/SCID (severe combined immunodeficient) mouse[1] Doses: 200 mg/kg (pharmacokinetic/PK/PK study) Route of Administration: Oral Experimental Results: t1/2=5 hrs (hrs (hours)). |
| References |
| Molecular Formula |
C27H23N3O4
|
|---|---|
| Molecular Weight |
453.489226579666
|
| Exact Mass |
453.168
|
| CAS # |
892243-35-5
|
| PubChem CID |
3675673
|
| Appearance |
Brown to reddish brown solid powder
|
| LogP |
5.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
34
|
| Complexity |
769
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1C=C(NC2=C3C4=C(C5C(C3=O)=CC=CC=5)ON=C4C(N3CCCCCC3)=C2)C=CC=1)O
|
| InChi Key |
UAEULQWANHYLGJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H23N3O4/c31-25-18-10-3-4-11-19(18)26-23-22(25)20(28-17-9-7-8-16(14-17)27(32)33)15-21(24(23)29-34-26)30-12-5-1-2-6-13-30/h3-4,7-11,14-15,28H,1-2,5-6,12-13H2,(H,32,33)
|
| Chemical Name |
3-[[12-(azepan-1-yl)-8-oxo-15-oxa-14-azatetracyclo[7.6.1.02,7.013,16]hexadeca-1(16),2,4,6,9,11,13-heptaen-10-yl]amino]benzoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~7.69 mg/mL (~16.96 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.77 mg/mL (1.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 7.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2051 mL | 11.0256 mL | 22.0512 mL | |
| 5 mM | 0.4410 mL | 2.2051 mL | 4.4102 mL | |
| 10 mM | 0.2205 mL | 1.1026 mL | 2.2051 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
